Search
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalThe treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. … Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalThis reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. … Currently dehydroascorbic acid is an experimental drug with no known approved indications.
Stem bromelain
go.drugbank.com/drugs/DB12249ApprovedThis action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … are currently not properly understood.
Ginkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical_Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Categories: Agents to Treat Airway DiseaseDemeclocycline
go.drugbank.com/drugs/DB00618ApprovedA tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Liotrix
go.drugbank.com/drugs/DB01583ApprovedIt consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion.
Categories: Agents used to treat hypothyroidismMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalIn 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. … Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).
Categories: N-methyl-D-aspartate Receptor AntagonistRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalIt was originally approved by the U.S. … FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label].
Carbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnThe compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.